You're not alone: the Hamilton area has a vibrant Crohn’s and colitis community, made up of people with inflammatory bowel disease, families, volunteers, and more. Throughout the year, we come together at meetings and events like the Gutsy Walk to share experiences, raise funds and heighten awareness.

There are almost 5,000 people with Crohn’s disease or ulcerative colitis in the Halton Region community. We understand the challenges you and your family may be facing – because we face them, too.
couple sitting looking at a laptop drinking a coffee

Caregiver Group Peer Support Event

Ready to connect with those who understand the challenges of being a caregiver to someone with Crohn's disease, ulcerative colitis, and other forms of Inflammatory Bowel Disease (IBD)?   ...

 • 
Virtual
 • 
A Man sitting and looking at Gutsy Peer Support on his mobile phone

Canada Wide Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   Join our upcoming Peer Connect ...

 • 
Virtual
 • 
A Gutsy Learning Series presenter in front of an audience

Gutsy Learning Series Presents : The IBD Journey

Join us online to learn more about managing Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD) at different stages of life. Discover how age-specific ...

 • 
 • 

Facebook

More on Facebook
 
Remember to bookmark this page.

March 2025

SunMonTueWedThuFriSat
2324252627281
2345678
9101112131415
16171819202122
23242526272829
303112345

News

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

 14 15 16 17 18 19 20 21 22 23